{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:44:28Z","timestamp":1781779468479,"version":"3.54.5"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1011000","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000}}],"reference-count":64,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["IP.2007.32011.011, IP.2007.32011.012, and IP.2007.32011.013"],"award-info":[{"award-number":["IP.2007.32011.011, IP.2007.32011.012, and IP.2007.32011.013"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TRIA2015-1102-PanACEA"],"award-info":[{"award-number":["TRIA2015-1102-PanACEA"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["262686"],"award-info":[{"award-number":["262686"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"\n Background<\/jats:title>\n \n Antibiotic treatments are often associated with a late slowdown in bacterial killing. This separates the killing of bacteria into at least two distinct phases: a quick phase followed by a slower phase, the latter of which is linked to treatment success. Current mechanistic explanations for the\n in vitro<\/jats:italic>\n slowdown are either antibiotic persistence or heteroresistance. Persistence is defined as the switching back and forth between susceptible and non-susceptible states, while heteroresistance is defined as the coexistence of bacteria with heterogeneous susceptibilities. Both are also thought to cause a slowdown in the decline of bacterial populations in patients and therefore complicate and prolong antibiotic treatments. Reduced bacterial death rates over time are also observed within tuberculosis patients, yet the mechanistic reasons for this are unknown and therefore the strategies to mitigate them are also unknown.\n <\/jats:p>\n <\/jats:sec>\n \n Methods and findings<\/jats:title>\n \n We analyse a dose ranging trial for rifampicin in tuberculosis patients and show that there is a slowdown in the decline of bacteria. We show that the late phase of bacterial killing depends more on the peak drug concentrations than the total drug exposure. We compare these to pharmacokinetic-pharmacodynamic models of rifampicin heteroresistance and persistence. We find that the observation on the slow phase\u2019s dependence on pharmacokinetic measures, specifically peak concentrations are only compatible with models of heteroresistance and incompatible with models of persistence. The quantitative agreement between heteroresistance models and observations is very good (\n \n \n \n \n \n \n R<\/mml:mi>\n <\/mml:mrow>\n \n a<\/mml:mi>\n d<\/mml:mi>\n j<\/mml:mi>\n <\/mml:mrow>\n \n 2<\/mml:mn>\n <\/mml:mrow>\n <\/mml:msubsup>\n =<\/mml:mo>\n 0.97<\/mml:mn>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n ).\n <\/jats:p>\n To corroborate the importance of the slowdown, we validate our results by estimating the time to sputum culture conversion and compare the results to a different dose ranging trial.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our findings indicate that higher doses, specifically higher peak concentrations may be used to optimize rifampicin treatments by accelerating bacterial killing in the slow phase. It adds to the growing body of literature supporting higher rifampicin doses for shortening tuberculosis treatments.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pcbi.1011000","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T14:31:45Z","timestamp":1681396305000},"page":"e1011000","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-6358","authenticated-orcid":true,"given":"Antal","family":"Martinecz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Boeree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Diacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Hemez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob E.","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9420-9005","authenticated-orcid":true,"given":"Pia","family":"Abel zur Wiesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"pcbi.1011000.ref001","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMra1413919","article-title":"Treatment of Tuberculosis","volume":"373","author":"CR Horsburgh","year":"2015","journal-title":"N Engl J Med"},{"key":"pcbi.1011000.ref002","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(10)62173-3","article-title":"Tuberculosis.","volume":"378","author":"SD Lawn","year":"2011","journal-title":"The Lancet"},{"key":"pcbi.1011000.ref003","doi-asserted-by":"crossref","first-page":"e1002842","DOI":"10.1371\/journal.pmed.1002842","article-title":"Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology","volume":"16","author":"KE Dooley","year":"2019","journal-title":"PLOS Med"},{"key":"pcbi.1011000.ref004","doi-asserted-by":"crossref","first-page":"e1002851","DOI":"10.1371\/journal.pmed.1002851","article-title":"Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs","volume":"16","author":"G Davies","year":"2019","journal-title":"PLOS Med"},{"key":"pcbi.1011000.ref005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1473-3099(10)70071-2","article-title":"Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis","volume":"10","author":"DJ Horne","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"pcbi.1011000.ref006","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-7-99","article-title":"Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia","volume":"7","author":"IC Shamputa","year":"2006","journal-title":"Respir Res"},{"key":"pcbi.1011000.ref007","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00888-17","article-title":"Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance","volume":"61","author":"JZ Metcalfe","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1011000.ref008","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3389\/fgene.2019.00477","article-title":"Effects of Host, Sample, and in vitro Culture on Genomic Diversity of Pathogenic Mycobacteria.","volume":"10","author":"AC Shockey","year":"2019","journal-title":"Front Genet"},{"key":"pcbi.1011000.ref009","doi-asserted-by":"crossref","first-page":"e1007726","DOI":"10.1371\/journal.ppat.1007726","article-title":"Heteroresistance: A cause of unexplained antibiotic treatment failure?","volume":"15","author":"VI Band","year":"2019","journal-title":"PLOS Pathog"},{"key":"pcbi.1011000.ref010","article-title":"Mechanisms and clinical relevance of bacterial heteroresistance","author":"DI Andersson","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"pcbi.1011000.ref011","article-title":"Definitions and guidelines for research on antibiotic persistence","author":"NQ Balaban","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"pcbi.1011000.ref012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature22361","article-title":"Deletion of a mycobacterial divisome factor collapses single-cell phenotypic heterogeneity","volume":"546","author":"EH Rego","year":"2017","journal-title":"Nature"},{"key":"pcbi.1011000.ref013","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/imr.12252","article-title":"Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses","volume":"264","author":"A Lenaerts","year":"2015","journal-title":"Immunol Rev"},{"key":"pcbi.1011000.ref014","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tube.2016.03.001","article-title":"Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB","volume":"98","author":"DA Barr","year":"2016","journal-title":"Tuberculosis"},{"key":"pcbi.1011000.ref015","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1126\/science.1099390","article-title":"Bacterial persistence as a phenotypic switch","volume":"305","author":"NQ Balaban","year":"2004","journal-title":"Science"},{"key":"pcbi.1011000.ref016","doi-asserted-by":"crossref","first-page":"16206","DOI":"10.1038\/nmicrobiol.2016.206","article-title":"Single-cell RNA-seq ties macrophage polarization to growth rate of intracellular Salmonella.","volume":"2","author":"A-E Saliba","year":"2016","journal-title":"Nat Microbiol"},{"key":"pcbi.1011000.ref017","doi-asserted-by":"crossref","first-page":"287ra73","DOI":"10.1126\/scitranslmed.aaa8760","article-title":"Classic reaction kinetics can explain complex patterns of antibiotic action.","volume":"7","author":"P Abel zur Wiesch","year":"2015","journal-title":"Sci Transl Med"},{"key":"pcbi.1011000.ref018","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1126\/science.aaf4762","article-title":"Biased partitioning of the multidrug efflux pump AcrAB-TolC underlies long-lived phenotypic heterogeneity","volume":"356","author":"T Bergmiller","year":"2017","journal-title":"Science"},{"key":"pcbi.1011000.ref019","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1128\/CMR.00058-14","article-title":"Antimicrobial Heteroresistance: an Emerging Field in Need of Clarity.","volume":"28","author":"OM El-Halfawy","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"pcbi.1011000.ref020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1099\/mic.0.000760","article-title":"The relevance of persisters in tuberculosis drug discovery","volume":"165","author":"S Mandal","year":"2019","journal-title":"Microbiology"},{"key":"pcbi.1011000.ref021","doi-asserted-by":"crossref","first-page":"954074","DOI":"10.3389\/fcimb.2022.954074","article-title":"Evolution of Mycobacterium tuberculosis drug resistance in the genomic era","volume":"12","author":"C Nimmo","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"pcbi.1011000.ref022","article-title":"Deciphering Within-Host Microevolution of Mycobacterium tuberculosis through Whole-Genome Sequencing: the Phenotypic Impact and Way Forward","volume":"83","author":"SD Ley","year":"2019","journal-title":"Microbiol Mol Biol Rev"},{"key":"pcbi.1011000.ref023","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1128\/AAC.02202-12","article-title":"Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis","volume":"57","author":"J Sarathy","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1011000.ref024","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s42003-021-02184-0","article-title":"Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse.","volume":"4","author":"G Magombedze","year":"2021","journal-title":"Commun Biol"},{"key":"pcbi.1011000.ref025","first-page":"1","article-title":"Greater Early Bactericidal Activity at Higher Rifampicin doses Revealed by Modeling and Clinical Trial Simulations","author":"RJ Svensson","year":"2018","journal-title":"J Infect Dis"},{"key":"pcbi.1011000.ref026","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy026","article-title":"The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis","volume":"67","author":"EM Svensson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pcbi.1011000.ref027","article-title":"High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo","volume":"6","author":"Y Hu","year":"2015","journal-title":"Front Microbiol"},{"key":"pcbi.1011000.ref028","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/fty065","article-title":"Estimating treatment prolongation for persistent infections.","volume":"76","author":"A Martinecz","year":"2018","journal-title":"Pathog Dis"},{"key":"pcbi.1011000.ref029","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"MJ Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"pcbi.1011000.ref030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.","volume":"17","author":"MJ Boeree","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pcbi.1011000.ref031","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/JCM.40.3.908-912.2002","article-title":"New simple and rapid test for culture confirmation of Mycobacterium tuberculosis complex: a multicenter study","volume":"40","author":"N Hasegawa","year":"2002","journal-title":"J Clin Microbiol"},{"key":"pcbi.1011000.ref032","first-page":"41","article-title":"MGIT procedure manual.","author":"H. Salman","year":"2006","journal-title":"Found Innov New Diagn"},{"key":"pcbi.1011000.ref033","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jac\/dku415","article-title":"The relationship between mycobacterium tuberculosis mgit time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations","volume":"70","author":"R Bowness","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"pcbi.1011000.ref034","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1093\/cid\/ciy623","article-title":"Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges","volume":"67","author":"G Magombedze","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pcbi.1011000.ref035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-00529-6","article-title":"Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration","volume":"7","author":"G Aljayyoussi","year":"2017","journal-title":"Sci Rep"},{"key":"pcbi.1011000.ref036","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/jac\/dkq374","article-title":"Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis","volume":"65","author":"JEM de Steenwinkel","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"pcbi.1011000.ref037","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000153314","article-title":"Evaluation of killing kinetics of anti-tuberculosis drugs on Mycobacterium tuberculosis using a bacteriophage-based assay","volume":"54","author":"N Marcel","year":"2008","journal-title":"Chemotherapy"},{"key":"pcbi.1011000.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1004749","article-title":"The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB.","volume":"12","author":"D Cadosch","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"pcbi.1011000.ref039","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0272-5231(21)00072-1","article-title":"Bacteriologic basis of short-course chemotherapy for tuberculosis","volume":"1","author":"J. Grosset","year":"1980","journal-title":"Clin Chest Med"},{"key":"pcbi.1011000.ref040","doi-asserted-by":"crossref","first-page":"e1002773","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization.","volume":"16","author":"N Strydom","year":"2019","journal-title":"PLOS Med"},{"key":"pcbi.1011000.ref041","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cpt.778","article-title":"A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses","volume":"103","author":"RJ Svensson","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"pcbi.1011000.ref042","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.micro.112408.134043","article-title":"Letting Sleeping dos Lie: Does Dormancy Play a Role in Tuberculosis?","volume":"64","author":"MC Chao","year":"2010","journal-title":"Annu Rev Microbiol"},{"key":"pcbi.1011000.ref043","doi-asserted-by":"crossref","first-page":"25273","DOI":"10.1074\/jbc.M803899200","article-title":"Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis","volume":"283","author":"A Koul","year":"2008","journal-title":"J Biol Chem"},{"key":"pcbi.1011000.ref044","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1099\/mic.0.033084-0","article-title":"Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability","volume":"156","author":"M Gengenbacher","year":"2010","journal-title":"Microbiology"},{"key":"pcbi.1011000.ref045","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin","volume":"51","author":"T Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1011000.ref046","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.3390\/ijms20163965","article-title":"Reaction Kinetic Models of Antibiotic Heteroresistance.","volume":"20","author":"A Martinecz","year":"2019","journal-title":"Int J Mol Sci"},{"key":"pcbi.1011000.ref047","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.molcel.2016.03.035","article-title":"Enhanced Efflux Activity Facilitates Drug Tolerance in Dormant Bacterial Cells","volume":"62","author":"Y Pu","year":"2016","journal-title":"Mol Cell"},{"key":"pcbi.1011000.ref048","doi-asserted-by":"crossref","first-page":"e0176522","DOI":"10.1371\/journal.pone.0176522","article-title":"Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis","volume":"12","author":"DJ Operario","year":"2017","journal-title":"PLOS ONE"},{"key":"pcbi.1011000.ref049","doi-asserted-by":"crossref","first-page":"e1009643","DOI":"10.1371\/journal.ppat.1009643","article-title":"Rifampicin exposure reveals within-host Mycobacterium tuberculosis diversity in patients with delayed culture conversion","volume":"17","author":"C Genestet","year":"2021","journal-title":"PLOS Pathog"},{"key":"pcbi.1011000.ref050","doi-asserted-by":"crossref","first-page":"e02255","DOI":"10.1128\/AAC.02255-20","article-title":"Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model","volume":"65","author":"ED Pieterman","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1011000.ref051","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"V. Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"pcbi.1011000.ref052","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"B Prideaux","year":"2015","journal-title":"Nat Med"},{"key":"pcbi.1011000.ref053","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.cct.2020.105938","article-title":"High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31\/ACTG A5349 phase 3 clinical trial.","volume":"90","author":"SE Dorman","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"pcbi.1011000.ref054","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"MZ Imperial","year":"2018","journal-title":"Nat Med"},{"key":"pcbi.1011000.ref055","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1128\/AAC.02243-12","article-title":"Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis.","volume":"57","author":"AH Diacon","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1011000.ref056","first-page":"690","article-title":"Pre-treatment mycobacterial sputum load influences individual on-treatment measurements.","volume":"94","author":"AH Diacon","year":"2014","journal-title":"Tuberc Edinb Scotl"},{"key":"pcbi.1011000.ref057","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02088-16","article-title":"Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies","volume":"61","author":"V De Jager","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"pcbi.1011000.ref058","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.tim.2017.03.007","article-title":"Integrating Lung Physiology, Immunology, and Tuberculosis.","volume":"25","author":"JB Torrelles","year":"2017","journal-title":"Trends Microbiol"},{"key":"pcbi.1011000.ref059","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis.","volume":"393","author":"J Furin","year":"2019","journal-title":"The Lancet"},{"key":"pcbi.1011000.ref060","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.4177","article-title":"Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure","volume":"22","author":"the Catalysis TB\u2013Biomarker Consortium","year":"2016","journal-title":"Nat Med"},{"key":"pcbi.1011000.ref061","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nm.3412","article-title":"Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing","volume":"20","author":"PL Lin","year":"2014","journal-title":"Nat Med"},{"key":"pcbi.1011000.ref062","doi-asserted-by":"crossref","first-page":"E4832","DOI":"10.1073\/pnas.1705385114","article-title":"Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations","volume":"114","author":"K Saito","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1011000.ref063","doi-asserted-by":"crossref","first-page":"e02192","DOI":"10.1128\/mBio.02192-18","article-title":"Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment","volume":"9","author":"K McAulay","year":"2018","journal-title":"mBio"},{"key":"pcbi.1011000.ref064","first-page":"e01478","article-title":"High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease","volume":"63","author":"TF Omansen","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1011000","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T14:31:45Z","timestamp":1682433105000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011000"}},"subtitle":[],"editor":[{"given":"James","family":"Gallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1011000","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.06.494966","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]}}}